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Edited by Maurice MontalAbstract The relevance of a point mutation at the C-terminal
end of the S6 helix (F468) and the introduction of C-type inacti-
vation in the blockage of hEag1 channels by astemizole, imipra-
mine and dofetilide was tested. C-type inactivation decreased
block by astemizole and dofetilide but not imipramine, suggest-
ing diﬀerent binding sites in the channel. F468C mutation in-
creased IC50 for astemizole and imipramine but in contrast to
HERG channels, only slightly for dofetilide. Together with mea-
surements on recovery of blocking, our observations indicate that
the mechanism of hEag1 blockage by each of these drugs is dif-
ferent, and suggest relevant structural diﬀerences between hEag1
and HERG channels.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Ether a` go-go; Potassium channels; Mutagenesis; Docking1. Introduction
Two channels of the Ether a´ go-go family [1] hEag1 and
HERG, have been reported as implicated in tumour progres-
sion [2]. In contrast to HERG, hEag1 shows unparalleled spec-
iﬁcity for tumour tissue [3,4] (except in the CNS) and its
inhibition using astemizole or imipramine reduces prolifera-
tion of tumour cells [3,5], both ideal features for a potential
anticancer target. Unfortunately, all known hEag1 blockers
(including imipramine and astemizole, [6–8]) also inhibit
HERG, which represents a serious diﬃculty for dissecting
the functions of hEag1 and from a practical point of view (be-
cause of HERG-related cardiac adverse eﬀects [9]). Therefore,
both the structural determinants responsible for hEag1 block-
age by compounds like astemizole and imipramine and the
possible diﬀerences in hEag1 and HERG blockage processesAbbreviations: hEag1, human ether-a´-go-go gene; WT, wild type; IC50,
half-maximal inhibitory drug concentration; AST, astemizole; IMI,
imipramine; DOF, dofetilide; NMA, N-methyl-astemizole
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doi:10.1016/j.febslet.2006.08.030will give us new insights for the future synthesis of speciﬁc
hEag1 blockers.
Previous studies from our group dealt with biophysical
details of the blocking mechanism of hEag1 channels by
astemizole and imipramine [10]. However, the structural deter-
minants important for these processes are still unknown. In
HERG channels, an intact C-type inactivation and a residue
at the C-terminal end of the S6 helix (F656) are crucial for
the blockage by several compounds [11–17]. The inﬂuence of
both features in hEag1 blockage by drugs, including astemizole
and imipramine is still unknown and was the goal of the pres-
ent work. We found clear diﬀerences in how the eﬀects of the
drugs are altered by mutations, and clear indications that at
the molecular level the blocking mechanisms for HERG and
hEag1 are distinct. Additionally, we performed in silico mole-
cular modelling that supports our interpretation of the exper-
imental ﬁndings in an independent way.2. Materials and methods
2.1. Molecular biology
Mutations were introduced into the pSGEM-hEAG1 [18] using the
QuikChange XL site-directed mutagenesis kit (Stratagene). All con-
structs were thereafter sequenced in full. The forward primer used to
generate hEag1F468C was (5 0–3 0; the reverse primer had the comple-
mentary sequence): TATGCCACCATCTGCGGGAATGTGACG.
hEag1T432S/A443S was constructed sequentially (ﬁrst T432S and
then A443S). The forward oligonucleotides used were: TCTCCTCG-
TTGTATTTCACAATGTCCAGCCTCACC (T432S) and TGGGA-
ACATCTCCCCATCCACAGACATTG (A443S).
Oocyte preparation and electrophysiological recordings were per-
formed as described elsewhere [19].
2.2. Data analysis
Curve-ﬁttings were performed using Igor Pro (WaveMetrics).
Half-maximal inhibitory drug concentration (IC50) values and Hill
coeﬃcients (h) were obtained through ﬁttings to the Hill equation.
Deactivation kinetics was determined by exponential ﬁtting. Data are
represented as means ± S.E.M., where n is the number of oocytes.
Statistical signiﬁcance was considered at P < 0.01 in two-tailed Student
t test.
2.3. Molecular modelling
Structural models of hEag1 and HERG were generated by homol-
ogy to the Kv1.2 Protein Data Bank entry 2A79 [20] for the open state.
Proteins were aligned with the program T-Coﬀee (Table 1) [21].
Aligned sequences were submitted to SWISS-MODEL [22] to obtain
the protein structures that were replicated in four identical subunits
and symmetrically placed around the pore axis to build the tetramericblished by Elsevier B.V. All rights reserved.
Table 1
Alignment of hEag1, HERG1 and Kv1.2 channels from the pore helix region to the ﬁnal residue of the S6 segment
Pore helix Filter Inner helix
hEag1 YISSLYFTMTST SVGFGNIAPSTI EKIFAVAIMMIGSLLYATIFGV
HERG1 YVTALYFTFSST SVGFGNVSPNTS EKIFSICVMLIGSLMYASIFGV
Kv1.2 IPDAFWWAVVST TVGYGDMVPTTG GKIVGSLCAIAGVLTIALPVPI
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steps of steepest descent, using AMBER [23]. Since energy minimisa-
tions were performed in the absence of solvent and lipid bilayer, the
protein backbone was restrained with a force constant of
7 Kcal mol1 A˚2.
Imipramine, astemizole and dofetilide were modelled in the proton-
ated state. Partial atomic charges of all the drugs were parameterised
by the ANTECHAMBER module of AMBER. Protein atomic charges
were deﬁned according to the AMBER99 force ﬁeld.
The docking procedure was performed using AUTODOCK 3.0 [24].
AUTODOCK performs the automated docking of a ﬂexible ligand in a
rigid receptor, minimizing an empirical energy function on a 3D grid.
All bound angles in the ligands were free to rotate. The grid was
deﬁned to cover the whole internal vestibule of the channels and the
energy was minimised by Lamarckian genetic algorithm. In order to
achieve a broad statistical analysis, every binding position search
was carried out by 150 docking runs [25]. The results were clustered
according to the root mean square distance (RMSD). Binding posi-
tions with a RMSD lower than 2 A˚ were placed in the same cluster
[25]. The binding position with the lowest energy in the group of most
populated cluster was selected for the Rclosest analysis.Fig. 1. Characterisation of hEag1 inhibition by NMA. (A) Chemical trans
currents elicited by the depicted voltage protocol applied at 0.05 Hz in the pre
line indicates the zero current level. (C) Time course of normalised current am
B (for clarity we indicated only the addition of 100 lMNMA), after NMA wa
measured at the end of the pulse at +40 mV and normalised to the amplitude b
dose–response curve (n = 10) obtained using the same protocol as desc
262.5 ± 22.5 lM and 1.4 ± 0.1. (D) hEag1 currents in inside-out patches in
obtained using the same protocol as in B. (E) Normalised dose–response curv
and Hill coeﬃcients were 30 ± 0.7 nM and 1.46 ± 0.05 for NMA, and 91 ± 52.4. Drugs
Astemizole, N-methyl-astemizole, dofetilide and MK-499, were di-
luted from a DMSO stock solution. The ﬁnal concentration of DMSO
was always 0.1%, a concentration that showed no eﬀects on hEag1 cur-
rents (data not shown). Imipramine was used from stocks in distilled
water. Astemizole and imipramine were purchased from Sigma. Pﬁzer
and Merck and Co. kindly supplied Dofetilide and MK-499, respec-
tively.3. Results and discussion
3.1. Charged astemizole blocks from the intracellular side
of hEag1 channels
Our laboratory [10] reported previously that in contrast to
imipramine, astemizole blocks a signiﬁcant amount of hEag1
current from the extracellular side. Although the kinetics of
this blockage are compatible with drug equilibration acrossformation of AST (1) into the charged derivate NMA (2). (B) hEag1
sence of increasing concentrations of NMA or 10 lMAST. The dashed
plitude (n = 4) in the presence of the NMA concentrations indicated in
shout, in the presence of 10 lMAST and after washout. Currents were
efore the addition of the NMA (Control in B). Inset, NMA normalised
ribed in B. The respective IC50 values and Hill coeﬃcients were
the presence of increasing concentrations of AST and NMA. Traces
es (n = 4–6). Currents were normalized as in C. Respective IC50 values
.9 nM and 1.11 ± 0.1 for AST.
Table 2
Concentration-dependent block of hEag1 WT, T432S/A443S and
F468C by AST, IMI and DOF
WT T432S/A443S F468C
AST 2.8 ± 0.1 (n = 9) 1.2 ± 0.1 (n = 10) 49.8 ± 2.1 (n = 7)
IMI 40.2 ± 0.3 (n = 10) 71.5 ± 1.7 (n = 8) 202.5 ± 5.9 (n = 11)
DOF 29.6 ± 1.1 (n = 9) 8.2 ± 0.6 (n = 10) 67.7 ± 4.2 (n = 10)
IC50 values in lM, obtained as in Fig. 2.
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cellular side of the hEag1 channel protein could not be ex-
cluded.
We synthesised the permanently charged, quaternary deriv-
ative of astemizole, N-methyl-astemizole (NMA; Fig. 1A).
Application of 100 lM NMA to the bathing solution reduced
current amplitude by 20% (IC50 > 100 lM; Fig. 1B and inset
Fig 1C). In contrast, in the same oocyte 10 lM astemizole
(AST) blocked 90% (Fig. 1B and C).
The lack of NMA eﬀect is not due to loss of aﬃnity for
hEag1. NMA applied to the intracellular side of inside-out
patches eﬃciently reduces the current amplitude (Fig. 1D). To-
gether with our previous studies [10], our data demonstrated
that both AST and NMA block the channel from the intracel-
lular side and that the charged form of AST (NMA) blocks
more eﬀectively (Fig. 1E).
3.2. The eﬀect of the mutations T432S/A443S and F468C on the
hEag1 blockage by astemizole (AST)
Intact C-type inactivation seems to be an important requisite
for the high-aﬃnity block by methanesulfonanilides in HERG
channels [11]. Similarly, introduction of C-type inactivation
into bovine Eag channels by a double mutation (T432S/Fig. 2. Concentration-dependent block of hEag1 WT, T432S/A443S and F
(0.05 Hz) after steady-state blockage with the indicated AST concentrations fo
(n = 7–10) obtained from experiments as described in A. Currents were measu
at +40 mV for T432S/A443S, and normalised to the amplitude of the current
values and Hill coeﬃcients were 2.8 ± 0.1 lM and 1.11 ± 0.05 for WT, 1.2 ± 0
for F468C.A443S) increases the potency of blockage by dofetilide [26].
These mutations in the context of hEag1 produce C-type inac-
tivation (Fig. 2A, T432S/A443S traces). Additionally, deacti-
vation of this mutant is slowed at all voltages between 70
and 140 mV, and the voltage-dependence of the activation
process is 10–15 mV left-shifted (data not shown).
AST did not aﬀect the activation or inactivation kinetics of
this mutant (data not shown), and we therefore determined
IC50 values by measuring hEag1 current after a steady state
blockage was achieved for each AST concentration, either at
the end of a +40 mV depolarizing steps for hEag1 wild type
(WT) or in the peak at +40 mV for hEag1 T432S/A443S.
Under these conditions, the double mutation increased the
potency of hEag1 blockage by AST (Table 2 and Fig. 2B).468C by AST. (A) hEag1 currents elicited by the depicted protocol
r WT, T432S/A443S and F468C. (B) Normalised dose–response curves
red at the end of the pulse at +40 mV in WT and F468C and at the peak
prior to the addition of the drugs (Control in A). The respective IC50
.1 lM and 1 ± 0.07 for T432S/A443S, and 49.8 ± 2.1 lM and 0.8 ± 0.04
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the binding of AST [27] and other blockers [16,17,28,29], but
the inﬂuence of the analogous residue (F468) in hEag1 block-
age had not been determined. F468C mutation did not alter
the activation or deactivation processes of hEag1 (data not
shown), although we cannot deﬁnitely discard any alteration
of channel kinetics because of the reduced expression levels
of the mutant, as reported for a mutation in HERG F656 [30].
hEag1F468C showed an IC50 for AST (after reaching stea-
dy-state blockage) 20 times higher than wild type channels
(Table 2 and Fig. 2B). This result constitutes the ﬁrst evidence
that F468 plays a crucial role in hEag1 blocking mechanisms,
as demonstrated for AST.
3.3. Eﬀects of mutations T432S/A443S and F468C on the hEag1
blockage by imipramine (IMI) and dofetilide (DOF)
AST and IMI compete for the inhibition of hEag1 channels,
suggesting that both drugs have an overlapping intracellular
binding site [10]. To test this hypothesis, we compared the
inﬂuence of C-type inactivation and F468C mutation in block
by IMI to the results obtained with AST (see above). Table 2
shows that the IC50 of IMI for hEag1 WT channels is 10 times
higher than that for AST, in good agreement with the diﬀer-Fig. 3. Diﬀerences in AST, IMI and DOF levels of block recovery between h
A443S and F468C currents prior to the block (C), after the steady-state block
were elicited by the same protocol as in Fig. 2. (B) Percentage of recovered cu
of washing was normalized to the total current blocked by each drug. The reco
and 93.7 ± 4%, respectively for WT, 6.7 ± 3.7%, 61 ± 8.2% and 6.6 ± 1%, resp
respectively for F468C. The bars represent the means ± S.E.M. of 5–8 oocytences determined previously in HEK293 cells [10]. Surpris-
ingly, in contrast to astemizole, the introduction of C-type
inactivation in hEag1 increased the IC50 of IMI rather than
reducing it. Although this diﬀerence could be due to diﬀerences
in state-dependence of binding, this result suggests a distinct
binding site for each drug. Interestingly, F468C mutation in-
creased IC50 suggesting that F468 is an important residue in
hEag1 blockage by both IMI and AST.
We extended our study to characterise the hEag1 blocking
process by dofetilide. The IC50 value obtained for DOF in
hEag1 WT channels is in agreement with that previously re-
ported for bovine Eag channels (31.8 lM, Table 2; [26]). The
introduction of inactivation increased the potency of blocking
by DOF, similarly to bEag [26]. This result suggests that the
molecular determinants of DOF blocking are very alike for
the human and the bovine Eag1 isoforms. Surprisingly, the
IC50 value obtained for dofetilide in hEag1 F468C is only 2-
fold greater than that for hEag1 WT. This loss of aﬃnity is
not as dramatic as that for HERG, where a mutation in
F656 increases the IC50 of DOF 100-fold [13]. Therefore,
although our data suggest that the F468 residue plays a role
in DOF binding to hEag1 channels, its importance seems to
be less than in HERG channels.Eag1 WT, T432S/A443S and F468C channels. (A) hEag1 WT, T432S/
(B) and after the washout (W) of 10 lMAST and 100 lM IMI. Traces
rrent at +40 mV after 5 min washing. The current recovered after 5 min
very percentages of AST, IMI and DOF were 72.1 ± 4.6%, 41.4 ± 2.4%
ectively for T432S/A443S, and 31.2 ± 7.2%, 96.2 ± 3.7% and 11 ± 1.5%,
es.
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AST-, IMI- and DOF-mediated blockage in diﬀerent ways
The eﬀects of introduction of C-type inactivation into hEag1
strongly suggest diﬀerent binding sites for IMI, AST and
DOF. We further explored this possibility with studies on
the recovery of block.
After blocking hEag1 WT current with either 10 lM AST,
100 lM IMI or 100 lM DOF (Fig. 3A and B), between 40%
and 90% recovery was achieved after 5 min wash, stronglyFig. 4. Mechanisms of block in hEag1 WT channels for DOF and MK-499.
499 (left traces) and DOF (right traces) and after washing (Washout). Traces
course of the recovery of block during washout of MK-499 and DOF. Current
the absence (Control) and presence of MK-499. Traces were produced accord
Right panel, tail current traces recorded at  90 mV, in the absence (Contro
level and the dotted line is the scaled tail current after addition of MK-499
kinetics before and after the blocking to be made. Additionally, exponential
1.31 ms for Control and 1.26 ms for MK-499.indicating that none of these drugs are trapped in the hEag1
channels during closing. In contrast, T432S/A443S and
F468C mutations signiﬁcantly slowed the recovery from block
by AST and DOF, but not by IMI. This is not due to the less
eﬃcient IMI-mediated hEag1 inhibition, because we obtained
the same results when lower concentrations of AST and
DOF were used, suﬃcient only to block 50% of the T432S/
A443S current (data not shown). Similarly, the slower recovery
from AST and DOF treatment is probably not due to the low(A) hEag1 currents before the block (Control), in the presence of MK-
were produced by the indicated protocol applied at 0.05 Hz. (B) Time-
s were measured and normalised as in Fig. 2. (C) hEag1 WT currents in
ing to the indicated protocol. The pulse to +40 mV had duration of 2 s.
l) and presence of MK-499. The dashed line indicates the zero current
to the Control current level, allowing a better comparison of closing
ﬁts to the currents are shown. The time constants of deactivation are
Fig. 5. Docking of AST, IMI and DOF within the cavity of the hEag1 K+ channel as constructed by homology. (A) Homology model showing the
S5–S6 domains of two hEag1 subunits with a docked molecule of AST (left panel) and DOF (right panel). F468 (red), T432 (blue) and A443 (yellow)
residues are shown as balls and sticks. (B) Close-up stereo views of the C-terminal end of the S6 helix showing the four F468 residues and the relative
position of the drugs. The upper panels and lower left panel correspond to hEag1 homology models with AST (blue, upper left), IMI (yellow, upper
right) and DOF (red, lower left). For AST and DOF and for better observation, the structures are rotated about the Y-axis with respect to the
structures in A as indicated on the left hand side of each schematic. The lower right panel is the HERG homology model with DOF and the F656
residues of the four subunits in orange. In all four panels, the closest distances between the aromatic rings atoms of the phenylalanine residues and the
drugs are indicated as dashed lines with the values in A˚. (C) Aromatic ring (p-stacking) interactions in terms of phenylalanine aromatic ring atoms
within the 3.4–4.5 A˚ of the drug phenyl ring atoms. The inter-atomic distances (Rclosest) close to this interval are indicated for AST-hEag1 docking
(empty circles), IMI-hEag1 docking (empty squares), DOF-hEag1 docking (empty triangles) and DOF-HERG docking (full triangles). The dashed
lines represent the Rclosest values of 3.4 and 4.5 A˚.
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we did not observe any signiﬁcant increase in the recovery in-
duced by 20 preconditioning pre-pulses of 400 ms to +40 mV
(data not shown). Therefore, the diﬀerences in the recovery
kinetics substantiate our hypothesis that the binding site in
hEag1 shared, at least to some degree, by AST and DOF is dif-
ferent from that of IMI.
3.5. Lack of trapping of dofetilide and MK-499 in hEag1
channels
Since in contrast to HERG channels [26,31] DOF does not
block hEag1 channels by a trapping mechanism, we tested
the blocking mechanism of hEag1 by MK-499, another meth-
anesulfoanilide.
MK-499 blocked hEag1 with an IC50 of 43.5 ± 4.7 lM
(n = 4, data not shown). Recovery was complete in 5 min
(Fig. 4A), with a time constant of 106.8 ± 0.7 s, in the same
range as for DOF (82.6 ± 0.9 s, Fig. 4B), strongly indicating
that block of hEag1 by MK-499 does not involve a drug trap-
ping mechanism. Additionally, a ‘‘foot in the door’’ mecha-
nism [17] does not appear to be implicated in the block of
hEag1 by MK-499, because the drug does not alter the kinetics
of deactivation, as can be deduced from the overlapping nor-
malised tail currents at 90 mV before and after blockage with
40 lM MK-499 (Fig. 4C). Exponential ﬁts to the tail currents
(Fig. 4C) gave time constants of deactivation of 1.3 ± 0.14 ms
before, and 1.3 ± 0.16 ms after blocking (n = 4).
These results strongly indicate that, unlike in HERG chan-
nels, both MK-499 and DOF dissociate from hEag1 before it
closes, and therefore blockage is not based on trapping of
the drug inside the channel during deactivation. Together with
the data concerning the diﬀerent inﬂuence of the Phe residues
in hEag1 and HERG blockage by dofetilide, our results
strongly suggest structural diﬀerences between the internal ves-
tibules of both channels.
3.6. Molecular modeling of hEag1-mediated blockage by AST,
IMI and DOF
In order to generate a molecular model of hEag1 to test our
hypotheses, we used the crystal structure of Kv1.2 channel [20]
as a template. It is important to note that Kv1.2 shows a Pro-
Val-Pro motif in the S6 domain that has been described to be
important for curving the inner helices during channel activa-
tion [32], while the hEag1 channel, like KvAP, has a Gly resi-
due in the corresponding position. We reached identical
conclusions using either KvAP or Kv1.2 as a template, proba-
bly because the Gly residue in KvAP also produces a curvature
of the inner helices [20]. In order to dock several open channel
blockers, we decided to only comment on our results obtained
employing Kv1.2. (open conformation), rather than KvAP
(close conformation).
Fig. 5A shows the docking model for AST and DOF in the
hEag1 vestibule. At ﬁrst glance, it is clear that the hydrophobic
rings of AST are closer than those of DOF to the Phe residue
rings. It is also interesting to note that, although the conforma-
tion of the inactivating mutant (T432S/A443S) could not be
predicted, our model suggests that the eﬀects observed in the
double mutant T432S/A443S could be allosteric, since neither
of these two residues are in close proximity to the drugs. Cur-
rent models predict that C-type inactivation of HERG results
in a twisting of the S6 helices and a repositioning of F656, to
increase the sensitivity of the channel [33]. Therefore, a similarmovement is possible in the inner helices of hEag1 channels
during C-type inactivation, thereby changing the position of
some amino acids and increasing the aﬃnity for AST and
DOF but not IMI. Further experiments will be necessary to
test this possibility. The in silico analysis also predicts that
other residues in the selectivity ﬁlter could interact with the
drugs and be important for their stabilization inside the inner
vestibule, as described for some residues at the base of the pore
helix of HERG and hEag1 [15,34].
Interestingly, molecular modelling also provides a possible
explanation for the eﬀects of the F468 mutation. It is accepted
that a p–p stacking interaction between two hydrophobic aro-
matic rings is energetically favourable dependent on the orien-
tation and proximity of the phenyl groups [35,36]. The distance
between the carbon atoms of the interacting rings must be be-
tween 3.4 and 4.5 A˚ [35,36]. To predict interactions between
the diﬀerent drugs and the F468 residues, we measured the dis-
tances (Rclosest) between the four Phe rings of the channel and
the atoms of the aromatic rings of the drugs. Fig. 5C indicates
all the Rclosest values close to this interval for the three diﬀerent
drugs. Only some phenyl groups of AST and IMI but not of
DOF show Rclosest values within the 3.4–4.5 A˚ interval with re-
spect to phenylalanine hydrophobic rings in the channel. This
result gives us a theoretical explanation for the weak eﬀect that
the F468 mutation has on the block achieved by DOF and the
large eﬀect observed for AST and IMI.
The usefulness of the Rclosest parameter as an indication for
possible p–p stacking interactions was validated by molecular
modelling of HERG (Fig. 5B, lower right) and studying the
docking of DOF. Interestingly, Rclosest analysis shows that
DOF is closer to the Phe residues in HERG than in hEag1
channels (Fig. 5C). This would agree with recent studies that
suggest that the orientation of the S6 aromatic residues with
respect to the central cavity of HERG diﬀers from those of
Eag channels [33]. Although other interactions must be impor-
tant for DOF binding to HERG channels, this data could ex-
plain why a mutation in these Phe residues aﬀects DOF-
mediated block more HERG than to hEag1.
In summary, the experimental diﬀerences detected in this
study between AST, IMI and DOF blocking processes to
hEag1 channels correlate well with information obtained from
our molecular modelling approach.
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